The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCIR.L Regulatory News (CIR)

  • There is currently no data for CIR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

10 Jun 2015 11:56

RNS Number : 7753P
Circassia Pharmaceuticals Plc
10 June 2015
 



THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA EXCEPT IN CERTAIN CIRCUMSTANCES, OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT

Further, this announcement is for information purposes only and shall not constitute an offer to sell or issue or the solicitation of an offer to buy, subscribe for or otherwise acquire any new ordinary shares of Circassia or Aerocrine AB in the United States or any jurisdiction in which any such offer or solicitation would be unlawful.

This announcement should be read in its entirety. In particular, you should read and understand the information provided in the "Important Notices" section.

10 June 2015

Circassia Pharmaceuticals plc

Result of General Meeting on 10 June 2015

Circassia Pharmaceuticals plc ("Circassia" or the "Company") announces that all resolutions set out in the notice of the General Meeting, contained within the combined prospectus and class 1 circular that was posted to shareholders on 18 May 2015 (the "Prospectus"), were passed at its General Meeting held today. A poll was conducted on each resolution proposed at the General Meeting and the number of votes cast for and against each of the resolutions, and the number of votes withheld, were as follows:

Resolution

For

%

Against

%

Withheld*

1

To approve the acquisition of Aerocrine AB by Circassia

 

139,160,162

 

99.99

 

10,390

 

0.01

 

391,310

2

To authorise the Directors to allot shares and dis-apply pre-emption rights in connection with the Placing and Open Offer**

 

139,160,162

 

99.99

 

10,390

 

0.01

 

391,310

* A vote withheld is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

** Passed as a special resolution.

The Record Date for entitlements under the Open Offer was 6.00 p.m. on 14 May 2015.

The Placing and Open Offer remains conditional upon Admission becoming effective and the Placing Agreement becoming unconditional in all respects, and not having been terminated in accordance with its terms.

Application has been made to the Financial Conduct Authority for 95,469,537 New Ordinary Shares of 0.08p each to be admitted to listing on the premium listing segment of the Official List and to the London Stock Exchange for such New Ordinary Shares to be admitted to trading on its main market for listed securities.

It is expected that Admission will become effective, and dealings in the New Ordinary Shares will commence, at 8.00 a.m. on 11 June 2015.

In accordance with LR 9.6.2, a copy of the resolutions passed at today's General Meeting will be submitted to the National Storage Mechanism and will be shortly available for inspection at www.morningstar.co.uk/uk/NSM.

A copy of this announcement has been posted on the Company's website, www.circassia.com.

Defined terms used herein have the meanings given to them in the Prospectus.

For enquiries, please contact:

Circassia Pharmaceuticals plc

+44 (0)1865 405 560

Steve Harris

Julien Cotta

Rob Budge

J.P. Morgan Cazenove

+44 (0)20 7742 4000

James Mitford

Alex Bruce

Peel Hunt LLP

+44 (0)20 7418 8900

James Steel

Clare Terlouw

FTI Consulting

+44 (0)20 3727 1000

Ben Atwell

Simon Conway

Mo Noonan

IMPORTANT NOTICE

Forward-looking statements

This Announcement contains forward-looking statements. None of the Company, J.P. Morgan Securities plc, J.P. Morgan Limited or Peel Hunt LLP undertakes any obligation or intends to revise or update any document (except, in the case of the Company, to the extent required by the Financial Conduct Authority (the "FCA"), the London Stock Exchange or by applicable law including the Listing Rules or the Disclosure Rules and Transparency Rules).

This Announcement and the information contained in it is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or from the United States (including its territories and possessions, any state of the United States except in certain circumstances and the District of Columbia, collectively the "United States"), Australia, Canada, Japan or South Africa or any other state or jurisdiction in which the same would be unlawful restricted, unlawful or unauthorised (each a "Restricted Territory"). This Announcement is for information purposes only and does not constitute an offer to sell or issue or the solicitation of an offer to buy, acquire or subscribe for shares in the capital of the Company in any Restricted Territory or to any person to whom it is unlawful to make such offer or solicitation. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions. Subject to certain exemptions, the securities referred to herein may not be offered or sold in any Restricted Territory or for the account or benefit of any national resident or citizen of any Restricted Territory. The shares issued pursuant to the placing and open offer (the "New Ordinary Shares") have not been and will not be registered under the United States Securities Act of 1933, as amended ("Securities Act") or the securities laws or with any securities regulatory authority of any other state or other jurisdiction of the United States, and may not be offered, sold or transferred, directly or indirectly, in the United States absent registration under the Securities Act or an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any other state or jurisdiction of the United States. Any offering of the New Ordinary Shares to be made in the United States will be made only to a limited number of "qualified institutional buyers" within the meaning of Rule 144A under the Securities Act pursuant to an exemption from registration under the Securities Act in a transaction not involving any public offering, and outside the United States in offshore transactions within the meaning of, and in reliance on, Regulation S under the Securities Act. No public offering of the shares referred to in this Announcement is being made in the United Kingdom, any Restricted Territory or elsewhere.

This Announcement does not constitute an extension into the United States of the offer mentioned in this Announcement, nor does it constitute nor form part of an offer to sell securities or the solicitation of an offer to buy securities in the United States. Aerocrine AB shareholders located or resident in the United States or who are acting for the account or benefit of such persons will not be eligible to participate in the tender offer for Aerocrine shares. Offer documents, including the offer document describing the terms of the offer and tender forms, have not and will not be distributed or sent into the United States.

The information in this Announcement may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorised. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

This Announcement has been issued by, and is the sole responsibility, of the Company. J.P. Morgan Securities plc, which is authorised by the Prudential Regulation Authority (the "PRA") and regulated in the United Kingdom by the FCA and the PRA, and J.P. Morgan Limited and Peel Hunt LLP, which are each authorised and regulated in the United Kingdom by the FCA, are each acting exclusively for the Company and no one else in connection with the proposed Acquisitions, Placing and Open Offer and Admission, will not regard any other person (whether or not a recipient of the Prospectus) as a client in relation to the proposed Acquisitions, Placing and Open Offer or Admission, and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, nor for providing advice, in relation to the proposed Acquisitions, Placing and Open Offer or Admission or any other matter referred to in this Announcement.

The New Ordinary Shares to be issued pursuant to the Placing and Open Offer will not be admitted to trading on any stock exchange other than the London Stock Exchange.

Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this Announcement.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMBBLFFEQFEBBX
Date   Source Headline
1st Sep 20225:45 pmRNSChange of Company Name
1st Sep 202211:00 amRNSResult of General Meeting and Change of Name
11th Aug 20227:00 amRNSProposed Change of Name and Notice of GM
29th Jul 202210:41 amRNSTotal Voting Rights
21st Jul 20223:30 pmRNSChange of Auditor
14th Jul 20227:00 amRNSTrading Update
5th Jul 20223:57 pmRNSHolding(s) in Company
30th Jun 202211:54 amRNSTotal Voting Rights
29th Jun 202211:00 amRNSUpdate regarding Beyond Air product approval
10th Jun 20221:06 pmRNSHolding(s) in Company
31st May 202211:08 amRNSTotal Voting Rights
27th May 20229:53 amRNSExtension of Block Admission
25th May 20224:41 pmRNSSecond Price Monitoring Extn
25th May 20224:35 pmRNSPrice Monitoring Extension
20th May 20227:00 amRNSGrant of Options
12th May 202212:04 pmRNSResult of AGM
12th May 20227:00 amRNSAGM Statement
3rd May 20224:01 pmRNSChange of Registered Office
29th Apr 202210:32 amRNSTotal Voting Rights
13th Apr 20226:17 pmRNSAnnual Report and Notice of AGM
1st Apr 20227:00 amRNSBlock listing Interim Review
1st Apr 20227:00 amRNSTotal Voting Rights
29th Mar 20222:18 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSBlock Admission
22nd Mar 20227:00 amRNSPreliminary Results
31st Jan 202210:24 amRNSTotal Voting Rights
28th Jan 20222:15 pmRNSHolding(s) in Company
13th Jan 20227:00 amRNSTrading Statement
4th Jan 202210:40 amRNSTotal Voting Rights
30th Nov 20217:00 amRNSTotal Voting Rights
29th Nov 20218:54 amRNSBlock Listing Application
5th Oct 20213:06 pmRNSExtension of Block Admission
30th Sep 20213:15 pmRNSBlock listing Interim Review
21st Sep 20215:18 pmRNSHolding(s) in Company
17th Sep 20217:00 amRNSDirector/PDMR Shareholding
16th Sep 20217:00 amRNSInterim Results - Ended 30 June 2021
1st Sep 20212:52 pmRNSTotal Voting Rights
30th Jul 20217:00 amRNSTotal Voting Rights
13th Jul 20217:00 amRNSFirst Half Trading Update
30th Jun 202111:15 amRNSTotal Voting Rights
26th May 20217:00 amRNSSettlement Agreement reached with Beyond Air
21st May 202110:58 amRNSResult of AGM
21st May 20217:00 amRNSAGM Statement
5th May 20216:30 pmRNSHolding(s) in Company
30th Apr 202112:32 pmRNSTotal Voting Rights
21st Apr 20217:00 amRNSAnnual Report and Notice of AGM
6th Apr 202112:56 pmRNSDirector/PDMR Shareholding
1st Apr 20219:00 amRNSBlock Listing Application
31st Mar 202112:14 pmRNSBlock listing Interim Review
24th Mar 20217:01 amRNSSubscription to raise £5 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.